Retinitis Pigmentosa clinical trials at UC Irvine

2 research studies open to eligible people

Showing trials for

  • Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

    open to eligible people ages 18-60

    This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (8.8M jCell) compared to sham-treated controls.

    Irvine, California and other locations

  • RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

    open to eligible people ages 18 years and up

    A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 15 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 3 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 12 months.

    Orange, California and other locations

Our lead scientists for Retinitis Pigmentosa research studies include .

Last updated: